Thrombolytic Checklist for Acute Ischemic Stroke
Administer IV alteplase 0.9 mg/kg (maximum 90 mg) over 60 minutes with 10% as initial bolus over 1 minute to eligible patients within 4.5 hours of symptom onset or last known well, prioritizing treatment as quickly as possible because every minute of delay worsens outcomes. 1
Time Windows and Eligibility
0-3 Hour Window (Broadest Eligibility)
- All adults ≥18 years including those >80 years old 1
- All stroke severities including severe strokes (high NIHSS) 1
- No upper age limit - benefit proven equally in patients <80 and >80 years 1
3-4.5 Hour Window (Additional Restrictions)
Eligible if patient meets ALL of the following 1:
- Age ≤80 years
- NIHSS score ≤25
- No history of BOTH diabetes AND prior stroke (either alone is acceptable)
- Not taking oral anticoagulants
- No imaging evidence of ischemic injury >1/3 MCA territory
Pre-Treatment Requirements
Blood Pressure
- Must be <185/110 mmHg before starting alteplase 1
- Can use antihypertensive agents to achieve this target
- Assess BP stability before initiating treatment
- Maintain BP <180/105 mmHg for 24 hours post-treatment 1
Blood Glucose
- Must be >50 mg/dL 1
- Correct hypoglycemia before treatment
Imaging Requirements
- CT or MRI must exclude intracranial hemorrhage 1
- Early ischemic changes of mild-to-moderate extent are acceptable 1
- Do NOT give if frank hypodensity or extensive clear hypoattenuation present 1
- Ischemic injury >1/3 MCA territory is a contraindication in the 3-4.5 hour window 1
Medication History Considerations
Antiplatelet Therapy - ACCEPTABLE
- Single antiplatelet (aspirin or clopidogrel): Give alteplase - benefit outweighs small increased sICH risk 1
- Dual antiplatelet therapy (aspirin + clopidogrel): Give alteplase - benefit outweighs probable increased sICH risk 1
- Do NOT give any antiplatelet drugs for 24 hours after alteplase 1
Anticoagulation
- Oral anticoagulants with INR ≤1.7: Give alteplase 1
- Oral anticoagulants with INR >1.7: Do NOT give - this is a contraindication
- End-stage renal disease on hemodialysis with normal aPTT: Give alteplase 1
Cerebral Microbleeds on MRI
- 1-10 microbleeds: Reasonable to give alteplase 1
- >10 microbleeds: Uncertain - individualize decision
Absolute Contraindications
Timing
- Symptom onset or last known well >4.5 hours 1
- Wake-up stroke with last known well >4.5 hours (unless DWI-FLAIR mismatch protocol used) 1
Imaging
- Any intracranial hemorrhage on CT/MRI 1
- Extensive regions of clear hypoattenuation/frank hypodensity 1
Dosing Algorithm
Standard dose: 0.9 mg/kg 1
- Maximum total dose: 90 mg
- Give 10% as IV bolus over 1 minute
- Give remaining 90% as IV infusion over 60 minutes
Critical caveat: A lower dose of 0.6 mg/kg was tested and found NOT equivalent to standard dosing - do not use reduced doses 1
Post-Treatment Monitoring
- Monitor BP every 15 minutes for first 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours
- Keep BP <180/105 mmHg for 24 hours 1
- No antiplatelet or anticoagulant therapy for 24 hours unless compelling indication where withholding poses substantial risk 1
- Monitor for orolingual angioedema (occurs in ~5% of patients)
- Assess for symptomatic intracranial hemorrhage
Key Clinical Pitfalls
Time is brain: The benefit of alteplase decreases significantly with every 15-minute delay 1. Do not waste time on unnecessary testing or consultations in clearly eligible patients.
Don't exclude based on mild symptoms: Even patients with mild deficits in the 0-3 hour window should receive treatment - the evidence supports benefit across all severity levels 1.
Age is not a barrier: Patients >80 years benefit equally in the 0-3 hour window 1. Only the 3-4.5 hour window has the age ≤80 restriction.
Prior antiplatelet use is NOT a contraindication: Both single and dual antiplatelet therapy are acceptable - give the alteplase 1.